Company Profile
NeuroSense Therapeutics Stock Price, News & Catalysts
- Ticker:
- NRSN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Israel and listed in the U
Stock performance
0.38 USD (+7.39%)
Close
Last updated: August 21, 2026
28.9M USD
Market cap
Why the stock is moving
As of Aug 21, 2026, NRSN closed up 7.39% at $0.3763. No new same-company headline was identified in the current news window.
Company overview
Business overview
NeuroSense Therapeutics is a biotechnology company focused on neurodegenerative diseases such as ALS and related conditions. Its story centers on trying to develop therapies for some of the hardest diseases in CNS medicine.
Geographic Base and Sector Classification
NeuroSense is headquartered in Israel and listed in the U.S. market. It sits in neuroscience biotechnology.
Business Model Characteristics
The company depends on clinical proof, translational confidence, and capital efficiency while advancing a narrow neurologic pipeline. Investors usually watch early data and strategic developments.
Position Within the Biotechnology Landscape
NeuroSense occupies a high-catalyst neurodegeneration niche within biotech. The stock is highly dependent on whether its programs can show meaningful neurologic benefit.
Future catalysts
- NeuroSense’s catalysts are primeC and its neurodegeneration programs, plus any update that shows the platform can still keep moving. The company still needs human proof.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of NeuroSense Therapeutics (NRSN)?
NeuroSense Therapeutics (NRSN) most recently closed at 0.38 USD, a +7.39% move versus the previous session.
What is the market cap of NeuroSense Therapeutics (NRSN)?
NeuroSense Therapeutics currently has a market capitalization of 28.9M USD on BioPharmSignal.
What does NeuroSense Therapeutics do?
NeuroSense Therapeutics is a biotechnology company focused on neurodegenerative diseases such as ALS and related conditions. Its story centers on trying to develop therapies for some of the hardest diseases in CNS medicine.
On which exchange is NRSN stock listed?
NeuroSense Therapeutics (NRSN) is associated with NASDAQ, Israel and listed in the U, Biopharma.
What is NeuroSense?
NeuroSense’s catalysts are primeC and its neurodegeneration programs, plus any update that shows the platform can still keep moving.
Which conditions is NeuroSense Therapeutics targeting with NeuroSense?
NeuroSense’s catalysts are primeC and its neurodegeneration programs, plus any update that shows the platform can still keep moving.
How does NeuroSense Therapeutics describe recent progress with NeuroSense?
NeuroSense’s catalysts are primeC and its neurodegeneration programs, plus any update that shows the platform can still keep moving.
What is Therapeutics?
NeuroSense Therapeutics is a biotechnology company focused on neurodegenerative diseases such as ALS and related conditions.